Updates on Outcome of EGM
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of minutes of the Extra Ordinary General Meeting (EGM) of the Company held on May 13, 2015.04-06-2015
04-06-2015
Code of Conduct of Fair Disclosure
Glenmark Pharmaceuticals Ltd has informed BSE about formulation and adoption of Codes under SEBI (Prohibition of Insider Trading) Regulations, 2015.04-06-2015
Allotment of Shares
Glenmark Pharmaceuticals Ltd has informed BSE that the Operations Committee of the Board of Directors of the Company, at its Meeting held on June 01, 2015 allotted 11,300 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.01-06-2015
Resignation of Director
Glenmark Pharmaceuticals Ltd has informed BSE that Mr. Natvarlal B. Desai, Director of the Company has resigned from the Board to be effective from June 01, 2015.29-05-2015
Board recommends Dividend
Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 29, 2015, inter alia, have recommended Dividend @ 200% i.e. Rs. 2/- per share (face value Re. 1/-) on the Equity Share Capital of the Company for the financial year 2014 - 2015 subject to the approval of the Shareholders at the ensuing Annual General Meeting.29-05-2015
Announces Q4 & FY15 Results, Management Discussion & Analysis and Results Press Release
Glenmark Pharmaceuticals Ltd has announced the following results for the quarter & year ended March 31, 2015:The Standalone Results are as follows:The Audited results for the Quarter ended March 31, 2015The Company has posted a net profit of Rs. 6704.30 million for the quarter ended March 31, 2015 as compared to Rs. 1516.68 million for the quarter ended March 31, 2014. Total Income has increased from Rs. 6872.56 million for...29-05-2015
Glenmark Pharmaceuticals receives ANDA approval for Desmopressin Acetate Tablets, 0.1 mg and 0.2 mg
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated May 29, 2015 titled "Glenmark Pharmaceuticals receives ANDA approval for Desmopressin Acetate Tablets, 0.1 mg and 0.2 mg".29-05-2015
Glenmark Pharmaceuticals receives tentative ANDA approval for Rufinamide Tablets USP
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated May 21, 2015, titled "Glenmark Pharmaceuticals receives tentative ANDA approval for Rufinamide Tablets USP."21-05-2015
Outcome of Preferential Issue Committee Committee
Glenmark Pharmaceuticals Ltd has informed BSE that the Preferential Issue Committee of the Board of Directors of the Company, at its Meeting held on May 19, 2015 allotted 1,08,00,000 Equity Shares of the face value of Re. 1/- each at a price of Rs. 875 per equity share to Aranda Investments (Mauritius) Pte Ltd., on preferential basis in terms of Chapter VII of SEBI (ICDR) Regulations and the applicable sections of the Companies Act, 2013.19-05-2015